Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of malignancy. Via a broad stimulation of the immune system, PDAC activates both antitumor immune responses and immunosuppressive mechanisms. We propose that new immunotherapeutic strategies for the management of PDAC should be de...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazhin, Alexandr V, Bayry, Jagadeesh, Umansky, Viktor, Werner, Jens, Karakhanova, Svetlana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850017/
https://www.ncbi.nlm.nih.gov/pubmed/24327934
http://dx.doi.org/10.4161/onci.25736
Descripción
Sumario:Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of malignancy. Via a broad stimulation of the immune system, PDAC activates both antitumor immune responses and immunosuppressive mechanisms. We propose that new immunotherapeutic strategies for the management of PDAC should be designed to specifically neutralize the immunosuppressive tumor microenvironment.

Ejemplares similares